Latest news

Thumbnail image for One third of cancer cases in England diagnosed as emergency

One third of cancer cases in England diagnosed as emergency

More than one third (34 percent) of patients with cancer diagnosed as an emergency in England had not visited their GP beforehand, a Cancer Research UK funded study published in the British Journal of General Practice has found.

25th April 2017

Thumbnail image for CHMP backs 11 medicines for European approval

CHMP backs 11 medicines for European approval

Eleven new medicines have taken a giant leap towards approval in Europe after winning backing from the European Medicines Agency’s Committee for Medicinal Product for Human Use (CHMP), including two that treat rare neurodegenerative conditions in children.

24th April 2017

Thumbnail image for US green light for Remicade biosimilar

US green light for Remicade biosimilar

US regulators have approved Renflexis, a biosimilar referencing Johnson & Johnson’s tumour necrosis factor (TNF) blocker Remicade (infliximab), across all eligible indications.

24th April 2017

Thumbnail image for Pharma heads call for decision on EMA relocation

Pharma heads call for decision on EMA relocation

Pharma chiefs in Europe are calling on heads of state to reach a prompt decision on the new location for the European Medicines Agency, which is to depart from the UK as a result of Brexit.

24th April 2017

Thumbnail image for BMS presents promising data for NASH drug

BMS presents promising data for NASH drug

Bristol-Myers Squibb’s investigational liver disease candidate has hit its targets in a mid-stage trial, supporting further research on the drug as a potential treatment for Nonalcoholic Steatohepatitis (NASH).

24th April 2017

Thumbnail image for NHS to ban sugary drinks in hospitals

NHS to ban sugary drinks in hospitals

Sugary drinks are to be banned in hospital shops from next year unless suppliers voluntarily take decisive action to cut their sales over the next 12 months, NHS England has announced.

21st April 2017

Thumbnail image for Data back first-line use of Novartis’ eltrombopag in SAA

Data back first-line use of Novartis’ eltrombopag in SAA

Novartis has announced the publication of data showing high response rates in patients with the rare blood disorder severe aplastic anaemia (SAA) taking its medicine eltrombopag, supporting its first-line use for the condition.

20th April 2017

Thumbnail image for GW’s Epidiolex on track for LGS filing mid-year

GW’s Epidiolex on track for LGS filing mid-year

GW Pharma’s Epidiolex has impressed again in a late-stage trial involving patients with the rare form of epilepsy Lennox-Gastaut Syndrome (LGS), significantly reducing the number of drop seizures experienced.

20th April 2017

Previous  --   1 2 3 4 5 6 7 8 9 10   --  Next

Latest jobs

View all

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download